General Information of Drug (ID: DMG7FLI)

Drug Name
UCART123 Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [1]
Blastic plasmacytoid dendritic cell neoplasm 2A60.5 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMG7FLI

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 3 receptor alpha (IL3RA) TTENHJ0 IL3RA_HUMAN CAR-T-Cell-Therapy [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin 3 receptor alpha (IL3RA) DTT IL3RA 1.807 3.926 2.678 3.573
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 3 receptor alpha (IL3RA) DTT IL3RA 8.71E-54 0.98 2.64
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03190278) Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia